FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma

On November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Source: FDA Center for Drug Evaluation and Research - What's New - November 17, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news